CY1115341T1 - Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων - Google Patents

Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων

Info

Publication number
CY1115341T1
CY1115341T1 CY20141100528T CY141100528T CY1115341T1 CY 1115341 T1 CY1115341 T1 CY 1115341T1 CY 20141100528 T CY20141100528 T CY 20141100528T CY 141100528 T CY141100528 T CY 141100528T CY 1115341 T1 CY1115341 T1 CY 1115341T1
Authority
CY
Cyprus
Prior art keywords
methods
intellacycular
double chain
single chain
double
Prior art date
Application number
CY20141100528T
Other languages
English (en)
Inventor
Sanjiv Ghanshani
Linh Q Le
Yi Liu
Lance E Steward
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1115341T1 publication Critical patent/CY1115341T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα περιγραφή αποκαλύπτει κατασκευάσματα έκφρασης τα οποία περιλαμβάνουν πρωτεΐνες μονής αλυσίδας, οι οποίες περιλαμβάνουν μία περιοχή βρόχου διπλής αλυσίδας, η οποία περιλαμβάνει μία εξωγενή θέση διάσπασης πρωτεάσης και μία πρωτεάση η οποία είναι δυνατόν να διασπά την εξωγενή θέση διάσπασης πρωτεάσης, η οποία ευρίσκεται εντός του βρόχου διπλής αλυσίδας, κυτταρικές συνθέσεις οι οποίες περιλαμβάνουν τέτοιο κατασκεύασμα έκφρασης και ενδοκυτταρικές μεθόδους μετατροπής της πρωτεΐνης μονής αλυσίδας προς τη μορφή διπλής αλυσίδας αυτής.
CY20141100528T 2010-01-25 2014-07-11 Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων CY1115341T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28696310P 2010-01-25 2010-01-25
EP11702755.7A EP2528940B1 (en) 2010-01-25 2011-01-24 Methods of intracellular conversion of single-chain proteins into their di-chain form

Publications (1)

Publication Number Publication Date
CY1115341T1 true CY1115341T1 (el) 2017-01-04

Family

ID=44146329

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100528T CY1115341T1 (el) 2010-01-25 2014-07-11 Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων
CY20161100700T CY1117797T1 (el) 2010-01-25 2016-07-19 Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161100700T CY1117797T1 (el) 2010-01-25 2016-07-19 Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων

Country Status (24)

Country Link
US (3) US8546108B2 (el)
EP (3) EP3034511A1 (el)
JP (2) JP5956350B2 (el)
KR (1) KR101930962B1 (el)
CN (1) CN102822196B (el)
AU (1) AU2016204285B2 (el)
BR (1) BR112012018526A2 (el)
CA (1) CA2788074C (el)
CL (1) CL2012002087A1 (el)
CY (2) CY1115341T1 (el)
DK (1) DK2528940T3 (el)
ES (2) ES2592856T3 (el)
HK (1) HK1179634A1 (el)
HU (1) HUE029962T2 (el)
IL (2) IL221095A (el)
MX (1) MX2012008650A (el)
NZ (1) NZ601472A (el)
PL (2) PL2684890T3 (el)
PT (2) PT2528940E (el)
RU (1) RU2569185C2 (el)
SG (1) SG182691A1 (el)
SI (2) SI2684890T1 (el)
WO (1) WO2011091370A1 (el)
ZA (1) ZA201205793B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822196B (zh) * 2010-01-25 2014-12-17 阿勒根公司 将单链蛋白质细胞内转化成它们的双链形式的方法
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9096886B2 (en) * 2011-03-11 2015-08-04 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
US9764009B2 (en) 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
DK3242884T3 (da) * 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
RU2627181C2 (ru) * 2015-12-29 2017-08-03 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Экспрессионный плазмидный лентивирусный вектор для гетерологичной экспрессии рекомбинантного человеческого белка cd47
US10308927B2 (en) 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
CN109055339B (zh) * 2018-09-19 2020-09-01 生工生物工程（上海）股份有限公司 Tev蛋白酶突变体、基因、生物材料、制备方法、试剂或试剂盒和应用
CN111019926B (zh) * 2018-10-10 2021-11-26 上饶市康可得生物科技有限公司 Tev蛋白酶变体、其融合蛋白及制备方法和用途
EP3851524A4 (en) * 2018-10-10 2022-05-18 Shangrao Concord Pharmaceutical Co., Ltd. PROTEASE VARIANT SCREENING METHOD AND PROTEASE VARIANT OBTAINED
CN111019925B (zh) * 2018-10-10 2022-08-23 上饶市康可得生物科技有限公司 筛选蛋白酶变体的方法以及获得的蛋白酶变体
JP7296660B2 (ja) * 2018-10-10 2023-06-23 上饒市康可得生物科技有限公司 Ｔｅｖプロテアーゼバリアント、その融合タンパク質、調製方法および使用
KR20200080749A (ko) * 2018-12-27 2020-07-07 주식회사 폴루스 N-말단의 메티오닌이 절단된 목적 단백질 발현용 유전자 발현 카세트 및 이를 이용하여 n-말단의 메티오닌이 절단된 목적 단백질을 생산하는 방법
JP6867452B2 (ja) * 2019-08-09 2021-04-28 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
WO2021062063A1 (en) * 2019-09-26 2021-04-01 Chan Zuckerberg Biohub, Inc. Improved variants of tev protease for biotechnological applications
CN113801866B (zh) * 2021-09-02 2022-08-16 无锡佰翱得生物科学有限公司 一种高效表达具有高活性及稳定性的重组tev酶及其制备方法和应用
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4321618A1 (en) * 2022-08-09 2024-02-14 NUMAFERM GmbH Variants of tev protease and uses thereof
CN116640196B (zh) * 2023-05-10 2024-02-06 山东农业大学 囊泡相关膜蛋白的相关蛋白vap1在抗马铃薯y病毒中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3949711B2 (ja) 1990-02-26 2007-07-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 昆虫ステロイドレセプターｄｎａ配列の同定及び発現
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
WO1994016083A1 (en) 1993-01-15 1994-07-21 Genetics Institute, Inc. Cloning of enterokinase and method of use
US6746859B1 (en) 1993-01-15 2004-06-08 Genetics Institute, Llc Cloning of enterokinase and method of use
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
AU5928100A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
EP2267010B1 (en) 1999-08-25 2014-05-07 Allergan, Inc. Activatable recombinant neurotoxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7132529B2 (en) 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US6836976B2 (en) 2003-03-18 2005-01-04 Solveig Laura Haugland Collapsible outdoor footwear and backpack
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1761558A1 (en) 2004-06-30 2007-03-14 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005271372B2 (en) 2004-08-04 2012-05-03 Allergan, Inc. Optimizing expression of active botulinum toxin type A
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US20060099710A1 (en) * 2004-11-10 2006-05-11 Donnelly Mark I Vector for improved in vivo production of proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
JP2008532549A (ja) * 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
EP1996178A2 (en) 2006-03-17 2008-12-03 Andover Healthcare, Inc. Organotellurium and selenium-based antimicrobial antimicrobial formulations and articles
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP1897887A1 (de) * 2006-09-08 2008-03-12 Universitätsklinikum Freiburg Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung
JP5404411B2 (ja) * 2006-11-22 2014-01-29 ノボ・ノルデイスク・エー／エス 活性化カルボキシペプチダーゼの製造方法
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
WO2010040134A2 (en) * 2008-10-04 2010-04-08 University Of Medicine And Dentistry Of New Jersey Independently inducible system of gene expression
CN102822196B (zh) * 2010-01-25 2014-12-17 阿勒根公司 将单链蛋白质细胞内转化成它们的双链形式的方法

Also Published As

Publication number Publication date
HK1179634A1 (en) 2013-10-04
PT2528940E (pt) 2014-06-24
CA2788074C (en) 2016-07-12
AU2011207445A1 (en) 2012-08-30
ES2592856T3 (es) 2016-12-01
US8546108B2 (en) 2013-10-01
HUE029962T2 (hu) 2017-04-28
CN102822196B (zh) 2014-12-17
EP2684890A1 (en) 2014-01-15
IL246310A0 (en) 2016-07-31
EP2528940B1 (en) 2014-05-14
SI2684890T1 (sl) 2016-10-28
MX2012008650A (es) 2012-11-23
PL2528940T3 (pl) 2014-10-31
CA2788074A1 (en) 2011-07-28
CN102822196A (zh) 2012-12-12
KR20120134117A (ko) 2012-12-11
BR112012018526A2 (pt) 2020-09-08
US9938514B2 (en) 2018-04-10
US20140030759A1 (en) 2014-01-30
RU2012136227A (ru) 2014-03-10
IL246310B (en) 2018-11-29
JP5956350B2 (ja) 2016-07-27
KR101930962B1 (ko) 2018-12-19
JP2016164205A (ja) 2016-09-08
JP6312745B2 (ja) 2018-04-18
RU2569185C2 (ru) 2015-11-20
US20120295330A1 (en) 2012-11-22
EP2528940A1 (en) 2012-12-05
WO2011091370A1 (en) 2011-07-28
EP3034511A1 (en) 2016-06-22
EP2684890B1 (en) 2016-04-20
CL2012002087A1 (es) 2013-01-11
ZA201205793B (en) 2013-05-29
AU2016204285A1 (en) 2016-07-14
PL2684890T3 (pl) 2016-11-30
IL221095A (en) 2017-06-29
PT2684890T (pt) 2016-07-28
NZ601472A (en) 2013-08-30
US9340813B2 (en) 2016-05-17
JP2013517797A (ja) 2013-05-20
US20160319265A1 (en) 2016-11-03
AU2016204285B2 (en) 2018-03-29
ES2488217T3 (es) 2014-08-26
SI2528940T1 (sl) 2014-07-31
SG182691A1 (en) 2012-08-30
CY1117797T1 (el) 2017-05-17
DK2528940T3 (da) 2014-07-14

Similar Documents

Publication Publication Date Title
CY1115341T1 (el) Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1122268T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
CY1123907T1 (el) Συνθεσεις και μεθοδοι για ρυθμιση αυξητικων παραγοντων
ECSP19034870A (es) Péptidos escindibles y proteínas insecticidas y nematicidas que los comprenden
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
CY1118970T1 (el) Στελεχη shigella με υπερφλυκταινωση
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
CY1119165T1 (el) Παραγωγα βενζιμιδαζολονης ως αναστολεις βρωμοπεδιου
WO2018160754A3 (en) Inducible monovalent antigen binding protein
ATE489465T1 (de) Gezielte integration in die ppp1r12c-position
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1116700T1 (el) Παρασκευη συνθετικου χολικου οξεος
CY1119926T1 (el) Νεοι μεταλλακτες prongf και χρησεις αυτων στην παραγωγη bhta-ngf
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
CY1118856T1 (el) Εμβολιο pcsk9
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
CY1116482T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης
CO6690815A2 (es) Métodos y composiciones para inmunoterapia para enfermedad neural
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.